



Universiteit
Leiden
The Netherlands

Understanding the complexity of TGF-beta signaling in cancer

Marvin, D.L.

Citation

Marvin, D. L. (2023, September 26). *Understanding the complexity of TGF-beta signaling in cancer*. Retrieved from <https://hdl.handle.net/1887/3642408>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3642408>

Note: To cite this publication please use the final published version (if applicable).



CHAPTER 2

Dynamic visualization of TGF- β /SMAD3 transcriptional responses in single living cells

Dieuwke L Marvin¹, Li You², Laura Bornes³, Maarten van Dinther¹, Niek Peters⁴, Hao Dang⁶, Sarah K. Hakuno⁶, Marten Hornsveld^{1,6}, Onno Kranenburg⁴, Jacco van Rheenen³, Jos H T Rohling⁵, Miao-Ping Chien², Peter ten Dijke^{1*}, Laila Ritsma¹

¹Oncode Institute and Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands

²Oncode Institute and Department of Molecular Genetics, Erasmus University Medical Center, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

³Oncode Institute and Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands

⁴UMC Utrecht Cancer Center, University Medical Center Utrecht and Utrecht University, Heidelberglaan 100, 3584CX Utrecht, The Netherlands

⁵Department of Cell and Chemical Biology, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands

⁶Department of Gastroenterology and Hepatology, Leiden University Medical Center, 2333 ZC Leiden, The Netherlands

Published in Cancers (Basel) 2022 May 19;14(10):2508. doi: 10.3390/cancers14102508

Abstract

Transforming growth factor- β (TGF- β) signaling is tightly controlled in duration and intensity during embryonic development and in the adult to maintain tissue homeostasis. To visualize the TGF- β /SMAD3 signaling kinetics we developed a dynamic TGF- β /SMAD3 transcriptional fluorescent reporter using multimerized SMAD3/4 binding elements driving the expression of a quickly folded and highly unstable GFP protein. We demonstrate the specificity and sensitivity of this reporter and its wide application to monitor dynamic TGF- β /SMAD3 transcriptional responses in both 2D and 3D systems *in vitro* as well as *in vivo* using live-cell and intravital imaging. Using this reporter in B16F10 cells, we observed single cell heterogeneity in response to TGF- β challenge, which can be categorized into early, late and non-responders. Because of its broad application potential, this reporter allows for new discoveries into how TGF- β /SMAD3-dependent transcriptional dynamics are affected during multistep and reversible biological processes.

Introduction

How a single cytokine can induce a wide variety of downstream responses in the same cell or in different cell types is a longstanding question in the signaling field^{1,2}. Transforming growth factor β (TGF- β) is a prototypical cytokine in this respect, as its biological responses are highly dependent on cellular context such as cell type and its differentiation state and/or the presence of other extracellular cues^{3,4}. TGF- β is part of a larger family of cytokines that also include activins and bone morphogenetic proteins (BMPs), which signal via selective transmembrane type I and type II serine/threonine kinase receptors and intracellular SMAD transcription factors. Examples of contextual-dependent biological roles include the action of TGF- β family ligands as morphogens during development in which the SMAD activation duration and intensity are critical determinants. TGF- β /activin can elicit opposing tumor promoting and suppressing effects in cancer⁴, which is attributed in part to changes in SMAD-interacting (transcription) factors, or rerouting through non-canonical signaling pathways⁵⁻⁸. Thus, TGF- β signaling spatio-temporal dynamics are determined by cell intrinsic and extrinsic factors, negative feedback loops and self-enabling responses, but how these contribute to different biological outputs is not well understood.

Given the multifunctional properties and wide variety of responses of TGF- β signaling, it is likely that dynamic control of signaling plays a role^{5,9}. Indeed, TGF- β signaling was shown to have a graded early response, and a switch-like sustained response¹⁰. Others have shown that the response to a TGF- β concentration is transient and adaptive, resulting in an instructive signal for patterning¹¹. However, many other questions remain, such as are dynamic TGF- β signaling responses heterogeneous, oscillating, and/or coupled to cellular behavior such as cell migration.

Signal encoded states are not merely on-or-off but are highly dynamic². This is likely to be of key importance during multistep biological responses, such as cell invasion, endothelial sprouting, etc. As such, signaling can be encoded by dynamic properties such as delay, duration, fold-change or frequency, resulting in extra layers to modulate signaling output^{1,2,9}. In order to detect these dynamic signals, fluorescent-based signaling reporters can be used to visualize and decode these changes in signaling pathways over time.¹

As mentioned above, TGF- β family members signal via intracellular SMAD transcription factors. Whereas activated TGF- β and activin type I

receptors mediate the activation of receptor regulated (R) mother against decapentaplegic homolog 2 (R-SMAD2) and R-SMAD3 by their carboxy (C) terminal phosphorylation on two serine residues, BMP receptors induce the C-terminal phosphorylation of R-SMAD 1, -5 and -8 proteins. Activated R-SMADs form heterodimeric and trimeric complexes with SMAD4 that translocate to the nucleus. The nuclear SMAD complexes bind to specific sequences in promoters of selected target genes, thereby regulating their transcription. The affinity of SMADs for DNA is low and SMADs require other DNA-binding transcription factors to efficiently bind to target promoters⁴. Target genes for TGF- β /SMAD3 signaling are, among others, *SERPINE1* (Serine proteinase inhibitor, Clade 1, Member 1, which encodes for plasminogen activator inhibitor 1 (PAI-1) protein), *SMAD7* and connective tissue growth factor (*CTGF*). Within the promoter region of *SERPINE1*, three 5'-CAGA-3' boxes were identified as direct binding sites for SMAD3 and 4¹². By multimerizing this Smad Binding Element, a 5'-CAGA-3' transcriptional reporter construct was created; 12 times 5'-CAGA-3' box repeat and a minimal adenovirus major late promoter (MLP) were cloned upfront of a reporter cDNA encoding luciferase¹². This is a widely used reporter system to interrogate TGF- β /SMAD3 signaling response in cells by preparing cell lysates of *in vitro* cultures or *in vivo* by bioluminescence, but lacks good temporal or single cell resolution^{13,14}.

Most signaling studies have been performed using population average methods. Advances of live cell imaging methods and fluorescent tagging of proteins or reporters driving the expression of fluorescent protein have allowed to monitor signaling dynamics in single cells in real time. TGF- β signaling dynamics has been measured by translocation of fluorescently-tagged (phosphorylated) SMAD2, 3 and 4 from cytoplasm to nucleus, one of the early events of the TGF- β signaling pathway^{9,11,15-18}. These studies and others have provided great insights in direct SMAD shuttling and signaling dynamics. Nuclear translocation of SMAD4, rather than SMAD2, can be correlated to a transcriptional response^{15,17}. Transcriptional output can also be determined by other factors than nuclear translocation of SMAD proteins^{19,20}.

Fluorescent-based transcriptional reporters allow for single cell visualization over time, and report for transcriptional output of signaling. The latter is more downstream of measuring SMAD2/3 phosphorylation or R-SMAD- or SMAD4 nuclear accumulation and therefore more subject to crosstalk with other signaling pathways. For example, SMAD transcriptional activity is determined by partner transcription factors of which the activation state is dependent on

activation by specific stimuli⁴. Luwor *et al* coupled a TdTomato fluorophore to the 12x 5'-CAGA-3' box to monitor effects of TGF- β on breast cancer cell migration *in vitro*²¹. This TGF- β /SMAD3 fluorescent reporter can give insights in transcription at a single time point and allows for cellular tracking at a single cell level. However, the stability of fluorescent proteins may hinder dynamic visualization over time and therefore this (and similar) reporters are not suited for visualizing transcription in a dynamic and temporal manner at single cell level. Taken together, there is a clear need for a dynamic transcriptional TGF- β reporter to assess TGF- β signaling *in vitro* as well as in living animals at single cell resolution. Measurement of the TGF- β /SMAD3 transcriptional temporal behavior in living cells will provide new insights into how dynamical features such as duration, intensity, and frequency of temporal signals, lead to specific cellular responses.

Materials and Methods

Reagents

TGF- β family ligands, dissolved in 4 μ M HCl/0.1% recombinant bovin serum albumin (BSA); TGF- β 1 (1 ng/ml unless indicated otherwise, 7666, R&D systems), TGF- β 2 (1 ng/ml unless indicated otherwise, kind gift from Joachim Nickel, University of Würzburg, Würzburg, Germany), TGF- β 3 (1 ng/ml unless indicated otherwise, kind gift from A. Hinck, University of Pittsburgh; this ligand is generally used, unless stated otherwise), Activin A (50 ng/ml, R&D systems), BMP2 (50 ng/ml, kind gift from Joachim Nickel, University of Würzburg, Würzburg, Germany), BMP6 (50 ng/ml, kind gift from Prof. Slobodan Vukicevic, University of Zagreb, Zagreb, Croatia), BMP7 (50 ng/ml, kind gift from Prof. Slobodan Vukicevic, University of Zagreb, Zagreb, Croatia), BMP9 (50 ng/ml, R&D systems). Selective small molecule T β RI kinase inhibitor SB505124 (1 μ M, DMSO, #3263, Tocris) and cycloheximide (50 ng/ml, C1988, Sigma) were used.

Generation of lentiviral TGF- β /SMAD3 reporter constructs

First, the pGLS3-CAGA₁₂-LUC plasmid²² was used to generate the pGLS3-CAGA₁₂-TdTomato construct by replacing the luciferase gene for the TdTomato gene using *Bam*HI/*Hind*III and *Xba*I. Next, *Cla*I and *Eco*RV/*Sma*I restriction sites were used to clone the CAGA₁₂-TdTomato fragment from the pGLS3-CAGA₁₂ into a pLV- phosphoglycerate kinase 1 (PGK)-puromycin vector to create the pLV-CAGA₁₂-TdTomato reporter, expressing TdTomato under transcriptional control of 12 5'-CAGA-3' SMAD3 response elements.

For subcloning, the CAGA₁₂-MLP element was amplified through polymerase chain reaction (PCR) using the CAGA₁₂-MLP FW and REV (containing *Age*1 restriction site) primers. The purified CAGA₁₂-MLP PCR product was digested using *Cla*1 and *Age*1, while the pLV vector was digested using *Cla*1 and *Eco*R1. The digested pLV vector was treated with shrimp alkaline phosphatase (SAP) to prevent self-ligation. The isolated pLV vector and CAGA₁₂-MLP promoter were used for subsequent cloning.

eGFP was amplified from CMV-d2eGFP-empty (gift from Phil Sharp (Addgene plasmid # 26164; <http://n2t.net/addgene:26164> (accessed on 3 September 2021); RRID:Addgene_26164)²³ through PCR using T7 FW GFP rev (including *Eco*R1 restriction site) primers (Table S1). The PCR product was digested using *Age*1 and *Eco*RI and was thereafter subcloned with the pLV vector and CAGA₁₂-MLP promoter using a 3-way ligation (1:1:1) through incubation overnight at 4°C with T4 ligase to generate pLV-CAGA₁₂-eGFP expressing eGFP under transcriptional control of 12 5'-CAGA-3' SMAD3 response elements.

To enhance eGFP folding speed and, thus, the appearance of fluorescence signal, we created a third construct with a superfolding GFP (sfGFP) harboring the super folding mutations (S30R, Y39N, N105, Y145F, I171V, A206V) in the eGFP. sfGFP-C1 (gift from Michael Davidson and Geoffrey Waldo (Addgene plasmid # 54579; <http://n2t.net/addgene:54579> (accessed on 3 September 2021); RRID:Addgene_54579)²⁴. sfGFP-C1 was isolated using *Eco*R1 and *Bsr*g1. Additionally, we engineered a PEST domain at the C-terminus of the construct to promote degradation by the pro-teasome once TGF- β signaling ceases. CMV-d2eGFP-empty (gift from Phil Sharp (Addgene plasmid # 26164; <http://n2t.net/addgene:26164> (accessed on 3 September 2021); RRID:Addgene_26164)²³ was used to amplify the destabilizing domain through PCR using D2 domain FW and REV primers (Table S1). Purified product was digested using *Eco*RI and *Bsr*g1. The purified destabilizing domain and sfGFP-C1 products were ligated by incubating on at 4°C with T4 ligase. The resulting dynGFP-C1 was digested with *Age*1 and *Eco*RI for to create the dynGFP insertion into the final vector. The pLV vector, CAGA₁₂-MLP promoter and dynGFP were ligated using a 3-way ligation using incubation overnight at 4°C with T4 ligase. This generated CAGA₁₂-dynGFP, expressing superfolder GFP with destabilizing domain under transcriptional control of 12 5'-CAGA-3' SMAD3 response elements. Plasmid sequences were verified using sanger sequencing using the eGFP FW, eGFP rev and PGK rev primers (Table S1).

Cells and culture methods

The following cell lines were used: Human embryonic kidney cells HEK293T (CRL3216™, ATCC), mouse melanoma cells B16F10 (CRL-6475™, ATCC) and YUMM4.1 (CRL-3366™, ATCC), human breast cancer cells MDA-MB-231 (HTB-26™, ATCC), mouse breast cancer D2.OR cells (kind gift from F.R. Miller²⁵), normal mammary gland NMuMG derivate NM18²⁶, human liver cancer cells (HepG2) (HB-8065™, ATCC), human acute monocytic leukemia cells (THP1) (TIB-202™, ATCC), mouse endothelial cells (MS1) (CRL-2279™, ATCC), pancreatic stellate cells (RLT-PSC) (kind gift from prof M. Löhr and dr. R. Heuchel²⁷ (Stockholm, Sweden)) and primary mouse fibroblasts. HEK293T, B16F10, MDA-MB-231, D.2OR, NM18, NIH3T3, HEPG2 and primary mouse fibroblasts were maintained in DMEM containing 10% FBS and 100 U/mL penicillin-streptomycin (15140122; Gibco). THP1 cells were maintained in RPMI-1640 medium containing 10% FBS and 100 U/mL penicillin-streptomycin (15140122; Gibco). Mouse melanoma cells YUMM4.1 and RLT-PSC cells were maintained in Dulbecco's Modified Eagle Medium DMEM/F12 containing 10% fetal bovine serum (FBS) and 100 U/mL penicillin-streptomycin. MS1 cells were maintained in aMEM containing 10% fetal bovine serum (FBS) and 100 U/mL penicillin-streptomycin. All cell lines were cultured in 37°C, 5%CO₂ incubators and routinely tested for absence of mycoplasma infections. All human cell lines were authenticated using short tandem repeat (STR) profiling.

Generation of CAGA₁₂-TdTomato, CAGA₁₂-GFP and CAGA₁₂-dynGFP cell lines

Lentiviruses were generated by HEK293T transfection with packaging constructs and the lentiviral constructs using standard protocols.²⁸ Cells were exposed to lentivirus containing pLV.CAGA₁₂-TdTomato, pLV.CAGA₁₂-GFP or pLV.CAGA₁₂-dynGFP, and polybrene (8 mg/ml) for 24 hours, and were allowed to recover for 1- 3 days. Transduced cells were then selected using 1 mg/ml puromycin for > 1 week.

B16F10 cells and RLT-PSC cells containing the CAGA₁₂-reporter were sorted using the BD FACS Aria III 4L (BD Biosciences, San Jose, CA, USA) at the Flow cytometry Core Facility (FCF) of Leiden University Medical Center (LUMC) in Leiden, Netherlands through sorting the top 20% fluorescence expressing cells after 24 hours (B16F10 and RLT-PSC pLV.CAGA₁₂-dynGFP) or 48 hours (B16F10 pLV.CAGA₁₂-TdTomato and B16F10 pLV.CAGA₁₂-GFP) of TGF- β 3 (1 ng/ml) stimulation. To generate clonal cell lines of B16F10 pLV.CAGA₁₂-dynGFP, cells were transduced with lentiviruses containing pLV.CMV-RFP-NLS. Transduced

cells were stimulated with TGF- β 3 (1 ng/ml) for 24 hours prior to FACS sorting of GFP+/RFP+ single cells into a 96 well plate using the BD FACS Aria III 4L (BD Biosciences, San Jose, CA, USA) at the Flow cytometry Core Facility (FCF) of Leiden University Medical Center (LUMC) in Leiden, Netherlands. Single cells were seeded in one 96 well and expanded, 3 clonal lines (clone 7, clone 8, clone 9) were selected for further experiments. FACS sorted cells were used within 1 month of sorting.

Colorectal cancer organoid culture

The colorectal cancer patient derived organoid (PDO) cultures used in this study were previously established and characterized²⁹. The culture conditions used were previously described.²⁹ Briefly, organoids were cultured in 75% Matrigel[®] domes (growth factor reduced basement membrane matrix, phenol red-free, Corning[®]). The culture medium conditions consist of Advanced DMEM/F12 (Gibco) with 1% Penicillin/Streptomycin (Gibco), 10 μ M HEPES, 1% Glutamax (Gibco), 100 ng/ml Noggin conditioned medium, 1X B27, 1.25 μ M N-acetyl-L-cysteine, 0.5 μ M A83-01 (Tocris), 10 μ M SB202190. In general, organoid medium was refreshed every 2-3 days. After around 1-2 weeks of culture, organoids were harvested and incubated with TrypLE Express (Gibco) at 37 °C for 1-5 minutes to obtain a single cell suspension. Residual TrypLE is washed out using Advanced DMEM/F12. Subsequently, the single cells were resuspended in 75% Matrigel/25% Advanced DMEM/F12 domes and plated in 6-, 12- or 24- wells culture plates.

The PDOs were stably transduced with the pLV.CAGA₁₂-dynGFP reporter and selected with puromycin and subsequent FACS-sorting of 24 hours stimulated TGF- β ₁ (5 ng/ml) dynGFP-positive cells. PDOs were dissociated into single cells and subsequently plated in a 384-well glass bottom plate (4581, Corning). All TGF- β ₁ stimulation experiments were conducted in organoid medium without noggin, A83-01, and N-acetyl-L-cysteine. PDOs were allowed to grow for 7-10 days after which experimental medium (5 ng/ml carrier-free recombinant human TGF- β ₁, R&D 240-B) was added. Organoids were scanned for 72 hours with 30 minutes time intervals using a 40X water objective lens on a Leica SP8X confocal microscope equipped with a culture chamber for adequate conditions (37 °C and 5.0% CO₂ overflow).

Pancreatic organoid co-culture

Resection derived pancreatic tumor organoid PDO1 (HUB-08-B2-029B), was obtained from the Hubrecht Organoid Technology Biobank (HUB)³⁰. Organoids

were cultured in Matrigel[®] (growth factor reduced basement membrane matrix, phenol red-free, Corning[®]) domes overlaid with advanced DMEM/F12 supplemented with Glutamine/Glutamax (200 nM 100x, Invitrogen), 100 UI/mL penicillin and 100 μ g/mL streptomycin (Thermo Fisher Scientific), B27 (1x, Invitrogen), recombinant Noggin, 100 ng/mL (Peprotech), Nicotinamide 10 μ M (Sigma), N-Acetyl Cysteine 1.25 μ M, (Sigma), Primocin 50 μ g (Invivogen), Gastrin 10 nM (Sigma), recombinant R-Spondin 3 200 ng/mL (Peprotech), recombinant FGF10A 100 ng/mL (Peprotech), recombinant EGF (5ng/ml), A83-01 500 nM (Selleckhem), WNT-surrogate - Fc fusion protein 0.5 nM (Utrecht Protein Express). The pancreatic stellate cell line RLT-PSC was a kind gift from prof M. Löhr and dr. R. Heuchel (Stockholm, Sweden)²⁷. RLT-PSC cells were transduced with pLentiPGK Hygro DEST H2B-mRuby2 (pLentiPGK Hygro DEST H2B-mRuby2 was a gift from Markus Covert, Addgene plasmid #90236) and selected with 100 mg/ml Hygromycin B (Sigma) for one week. Subsequently RLT-PSC-mRuby2 were transduced with pLV.CAGA₁₂-dynGFP and selected with 1 mg/ml Puromycin (Invitrogen). After puromycin selection, cells were stimulated with TGF- β 3 (1 ng/ml) for 24 hours and FACS sorted for the top 20% cells expressing dynGFP.

For co-culture experiments, PDOs and RLT-PSCs were trypsinized to single cell suspensions; PDO and RLT-PSC cells were then mixed together in a 1:10 ratio in RLT-PSC medium containing 1% Matrigel. The mixtures were plated in ultra-low attachment 96-well round-bottom plates (Costar; n=1000 PDO and n=10.000 RLT-PSC cells per well), centrifuged (1200 RPM, 1 minute) and incubated overnight (37 °C, 5% CO₂). The next day, the formed aggregates were collected and the supernatant was removed. Individual aggregates were taken up in 100% Matrigel and plated in flat-bottom 96-well plates (Greiner) which were pre-coated with 50 μ l Matrigel. PDO medium was added after polymerisation of the Matrigel. The co-culture experiment was performed without the presence of the TGF- β kinase inhibitor A83-01, unless specifically indicated. The different experimental conditions containing either TGF- β 1 (5 ng/ml), A83-01 (500nM, Selleckhem) or control pancreatic organoid medium without A83-01 (endogenous condition) was added and refreshed every 2 days for a period of 5 days. At day 4, A83-01 (500nM, Selleckhem) was added to the endogenous condition. Photos were taken daily using the Cytation 5 live-cell imaging microscope (Agilent).

Flow cytometry analysis

Cells were treated with TGF- β 3 (1 ng/ml), SB505124 (1 μ M), cycloheximide (50 mg/ml), or vehicle solvent control for the indicated time points. Samples treated

with TGF- β type I receptor kinase inhibitor SB505124 were pre-stimulated with TGF- β 24 hours (CAGA₁₂-dynGFP) or 48 hours (CAGA₁₂-TdTomato/ CAGA₁₂-GFP) prior to SB505124 treatment. To collect cells, cells were trypsinized and resuspended in DMEM containing 10% FBS and pen-strep. Sample were washed and resuspended in PBS containing 0.2% BSA. For cell cycle analysis, cells were treated with Hoechst33342 (20 mg/ml) (#62249, Thermo Fisher) for 45 minutes at 37 °C prior to trypsinization of cells, and treated with TGF- β (1 ng/ml) for 2 hours prior to trypsinization of cells. Fluorescence was directly measured by BD LSRII (BD systems). Flow cytometry data was analyzed using FlowJo™ (v10).

rt-qPCR

B16F10 CAGA₁₂-TdTomato/ CAGA₁₂-GFP/ CAGA₁₂-dynGFP cells were treated with TGF- β 3 (1 ng/ml) and/or SB505124 (1 μ M). Samples treated with SB505124 were pre-stimulated with TGF- β 24 hours (CAGA₁₂-dynGFP) or 48 hours (CAGA₁₂-TdTomato/ CAGA₁₂-GFP) prior to SB505124 treatment). Total RNA extraction was performed using the NucleoSpin RNA II kit (Macherey-Nagel). 1 mg of RNA was used for cDNA synthesis using the Revert Aid First Strand cDNA synthesis kit (Thermo Fisher). Quantitative PCR was performed using SYBBR GoTaq qPCR master mix (Promega) and 0.5 μ M of primers targeting (dyn)GFP, SMAD7, *Serpine1*, *Ctgf*, *Gapdh* and *Hprt* (Table S2). RT-qPCR was performed on the CFX connect Real-Time PCR detection system (Bio-Rad). Measurements were performed in technical duplicate and independent biological triplicate, target gene expression was normalized for *Gapdh* and *Hprt* expression.

Western blotting

Protein lysates were harvested in Laemmli buffer (0.12 M Tris-HCl pH 6.8, 4% SDS, 20 % glycerol, 35 μ M β -mercaptoethanol and bromophenol blue) and boiled for 5 minutes. Western blotting was performed using standard procedures. Membranes were blocked in 5 % non-fat dry milk for 1 hour at room temperature and incubated with primary antibody in 2.5 % non-fat dry milk overnight at 4 °C. Primary antibodies used were GFP (sc-8334, Santa Cruz), PAI-1 (ab222754, Abcam), phospho-SMAD1 and 2³¹, GAPDH and Vinculin (V9131, Sigma). As the C-termini of SMAD3, and BMP R-SMAD1 and -5 are identical, p-SMAD2 was used to assess T β RI activity. Experiments were performed in independent biological triplicate, representative images are shown.

CAGA₁₂-luciferase assay

B16F10 cells were seeded in a 24-well plate and transfected with plasmids containing the CAGA₁₂-luc transcriptional reporter and SV40 promoter controlled β -gal cDNA expression vector expressing β -galactosidase using *polyethylenimine* (PEI). Cells were washed and stimulated with TGF- β 3 (1 ng/ml) and/or SB505124 (1 μ M) overnight. Cells were lysed and luciferase and β -galactosidase signal were measured with a PerkinElmer plate reader. Luciferase signals were corrected for signals in untransfected control samples and normalized for β -galactosidase expression. Experiments were performed by integrating results of three independent wells.

Live cell imaging using Incucyte®

CAGA12-GFP/ CAGA12-dynGFP reporter B16F10 cells were plated in a 96 well plate (#3595, Corning) and were stimulated with TGF- β 3 (1 ng/ml or otherwise indicated), SB505124 (1 μ M), cycloheximide (50 mg/ml), or vehicle solvent control for the indicated time points. Measurements were taken every 2 hours using the Incucyte® S3 live-cell analysis system using brightfield and GFP laser with 300 msec exposure. Fluorescence intensity and confluency was measured using Incucyte® S3 Software. Experiments were performed by integrating results of three independent wells. Signal over background (s/b) scores were calculated by dividing the average fluorescence intensity upon TGF- β stimulation by unstimulated controls at the indicated timepoints. Z' scores were calculated using the following formula:

$$Z' = \frac{3 * (STDev_{pos} + STDev_{neg})}{|AVG_{pos} - AVG_{neg}|}$$

Confocal microscopy

B16F10 CAGA₁₂-TdTomato/ CAGA₁₂-GFP/ CAGA₁₂-dynGFP were plated in a chambered coverslip (80826 Ibidi). Cells were treated with TGF- β 3 (1 ng/ml) and/or SB505124 (1 μ M) for 24 hours (CAGA₁₂-dynGFP) or 48 hours (CAGA₁₂-TdTomato/ CAGA₁₂-GFP). Live cells were stained with Hoechst 33342 (10 mg/ml) (#62249, Thermo Fisher) for 15 minutes, prior to imaging. Confocal images were taken on a Leica TCS SP5 confocal laser scanning microscope.

Intravital imaging experiments

Experimental Model and Subject Details

All mice were housed under a 12 hours light/dark cycle and under specific pathogen free laboratory conditions receiving food and water *ad libitum*. All

experiments were approved and performed according to the guidelines of the Animal Welfare Committees of the Netherlands Cancer Institute, protocol code 9.1.957. The Netherlands. *MMTV-PyMT*; *R26-mTmG*; *E-cad-mCFP* transgenic mice were crossed to generate donor organoids, therefore *MMTV-PyMT* and *R26-mTmG* mice^{32,33} (mice were purchased from Jackson Laboratory, Sacramento, CA, USA), *Ecad-mCFP* mice³⁴ were a gift from Hans Clevers. The process of isolation and culturing of the donor mouse organoids are described in³⁵. As acceptors for orthotopic transplantation 8 to 16 weeks old female Friend Virus B NIH Jackson, mice (referred in the text to as FVB) were used. For transplantation, 250000 single cells were plated 3 days prior of transplantation. At the day of transplantation BME was dissolved, by mechanical disruption and cells were dissolved in 100 ml Basal Membrane Extract (BME) type 2 (RGF BME type 2 PathClear):PBS and injected into the fat pad of the 4th mammary gland of acceptor mice.

PYMT organoid generation and viral transductions

MMTV-PyMT; *R26-mTmG*; *E-cad-mCFP* transgenic mice spontaneously developed mammary tumors at the age of 8-14 wks. Upon tumor formation, mice were sacrificed and mammary tumor organoids were isolated from one donor. Mammary tumors were minced and enzymatically digested gently shaken for 30 minutes at 37°C in digestion mix (0.2% trypsin (from bovine pancreas, Sigma) and 0.2% collagenase A (Roche)). The digested tumors were spun down and cell fragments were embedded in Basal Membrane Extract (BME) type 2 (RGF BME type 2 PathClear). Mammary tumor organoid medium contained DMEM/F12 Glutamax (Gibco), 2% B27 (Invitrogen), 10 ng/ml FGF.

For lentiviral production, HEK293T cells (ATCC® CRL-1573™), were plated at 7x10⁶ cells per 15 cm dish. After 24 hours, cells were transfected with 32 mg of the pLV. CAGA₁₂-dynGFP lentiviral plasmid, plus the lentiviral packaging and envelope expression plasmids (pMDL, REV, VSV-G) diluted in 1ml of Optimem (Gibco) and 150 ml PEI. After mixing and 5 minutes incubation at RT the mixture was dropwise added to the dish. Two days after transfection, supernatant of transfected cells was harvested, filtered through 0.45 mm filters, and concentrated using Amnico Ultra centrifugal filter units (Merck). For lentiviral organoid transduction, organoids were dissociated into single cells by 10 minutes digestion at 37 °C in TrypLE (Gibco) followed by mechanical disruption. Single cells were resuspended in concentrated virus supplemented with Y-27632 (1/1000, #M1817, Abmole) and polybrene and spin incubated at RT for 60 minutes at 600 rpm in a 48-well plate. After incubation for 6 hours at 37 °C, the cell suspension was collected and single cells were embedded

in BME. Mammary tumor organoid medium was supplemented with Y-27632 (1/1000, #M1817, Abmole) until organoids recovered.

After recovery and expansion, organoids were treated for 48 hours with 5 ng/ml TGF- β 1. Organoids were collected washed and dissociated into single cells by enzymatic digestion for 10 minutes at 37 °C in TrypLE and mechanical disruption. Cells were resuspended in FACS buffer (PBS+ 5 μ M EDTA, 2% FBS) and mTdTom⁺/GFP⁺ cell population was sorted on a FACS ARIA Fusion (BD biosciences) to >90% purity.

Single cell live cell imaging

Before conducting experiments, 100K cells B16F10 CAGA₁₂-dynGFP containing a pLV.CMV-RFP-NLS were seeded on fibronectin (0.1 mg/mL)- coated 14mm-glass bottom dishes in DMEM medium without phenol red. Experiments were performed 16-24 hours after plating on the glass-bottom dishes. The cells were simultaneously imaged using 460 nm (dynGFP) and 532 nm (RFP-NLS) excitation for 1 day at 1 frame per 3 minutes. For imaging, a field of view (size ~2.5x3.5mm) was chosen, containing a fraction of the cells. For the Clone 7 data, 2575 cells were detected by the end of day 1; for the Clone 9 data, 10748 cells were detected by the end of day 1. We have successfully tracked 83.1% (= 2139/2575) of the Clone 7 population, and 96.9% (= 10414/10748) of the Clone 9 population.

The movement of CAGA₁₂-dynGFP B16F10 cells expressing red fluorescent protein (RFP)-containing a nuclear localization signal (NLS) was tracked by RFP signal and analysed using the mTGMM (modified Tracking using Gaussian Mixture Model) cell tracking algorithm³⁶. In brief, the intensity profile of individual nuclei/cell was modelled as a 2D Gaussian distribution. Nuclei tracking was done by forwarding every Gaussian from time point t to $t + 1$ using Bayesian inference, with a priori knowledge that the position, shape, overall intensity of nuclei could not change dramatically between two consecutive time points. After nuclei/cell detection and tracking, nuclei masks and positions over time were recorded. The RFP signal of individual cells was then extracted from the GFP channel over time using the nuclei/cell masks.

After segmentation and tracking of the cells, the GFP signal of individual cells from the GFP channel overtime was extracted. A heatmap was generated to visualize the dynamical process over all cells of this dataset. The dataset could be further classified into groups via Euclidean distance-based hierarchical clustering analysis. After the analysis, two distinct groups were clearly observed:

the first group had the GFP intensity trace going up around 300 minutes and the second group had the GFP intensity trace going up around 700 minutes. We therefore called these two groups the early and late responders, respectively.

Statistical analysis

Experiments were performed in independent biological triplicates, unless otherwise indicated. Error bars represent \pm standard error of the mean (SEM), unless otherwise indicated. Statistics were calculated using GraphPad Prism 7 software.

Results

Generation of a dynamic TGF- β /SMAD3 transcriptional reporter, CAGA₁₂-dynGFP

With the aim to generate a TGF- β /SMAD3 transcriptional reporter that is capable of monitoring signaling dynamics at the transcriptional level in single living cells, we created the lentiviral pLV-CAGA₁₂-sfGFP-PEST-PGK-Puro vector, also referred to as dynamic GFP (CAGA₁₂-dynGFP) reporter. To enhance the appearance and clearance of the fluorescence signal compared to the enhanced (e)GFP reporter (pLV-CAGA₁₂-EGFP-PGK-Puro) we used an eGFP with so-called super folding mutations (S30R, Y39N, N105, Y145F, I171V, A206V)²⁴ and fused a PEST domain (a peptide sequence that is rich in proline (P), glutamic acid (E), serine (S), and threonine (T)) at the eGFP C-terminus to promote degradation by the proteasome once TGF- β -induced transcription ceases (Figure 1A)^{23,37}. To compare our fast folding, fast degrading CAGA₁₂-dynGFP with the previously used fluorescent CAGA₁₂-GFP and CAGA₁₂-TdTomato reporter, we additionally created a pLV-CAGA₁₂-GFP-PGK-Puro vector and a pLV-CAGA₁₂-TdTomato-PGK-Puro vector.

To assess the kinetic responsiveness of the transcriptional reporters to TGF- β , the constructs were transduced by lentiviral infection into the murine melanoma cell line B16F10. The B16F10 cells were found, based on TGF- β -induced CAGA₁₂-luciferase transcriptional reporter assay and SMAD2 phosphorylation, to be highly responsive to TGF- β stimulation, while having no background TGF- β signaling in unstimulated conditions (Figure S1A, B). As expected, the cells stably expressing the CAGA₁₂-TdTomato, CAGA₁₂-GFP and CAGA₁₂-dynGFP showed fluorescence reporter activity after addition of TGF- β and not when the cells were co-treated with a selective T β RI kinase inhibitor

SB505124 and TGF- β (Figure 1B). The 5'-CAGA-3' DNA boxes were previously reported to be specific for SMAD3 and SMAD4 binding, and thus respond to TGF- β isoforms and activin, but are unresponsive to BMP cellular stimulation. Consistent with these results, we observed that the CAGA₁₂-dynGFP reporter cells responded to TGF- β 1, -b2, -b3, and Activin A (albeit weakly), but not to BMPs (Figure S1C). Treatment of B16F10 CAGA₁₂-dynGFP cells with TGF- β 1 or TGF- β 3 resulted in a similar dynGFP fluorescence increase (Figure S1E). The differential level of fluorescence signal induced by TGF- β isoforms and activin correlated with the differential ability of these ligands to induce SMAD2 phosphorylation (Figure S1B).


As a first experiment to assess TGF- β -induced transcriptional responses with CAGA₁₂-dynGFP, we compared this reporter side-by-side to the widely used CAGA₁₂-luciferase reporter in B16F10 cells. Indeed, the CAGA₁₂-dynGFP reporter showed similar results using an end-point assay on lysed cells by plate reader (Figure S1A). Additionally, protein levels of dynGFP and target protein PAI-1 followed similar trends upon TGF- β and SB505124 treatment (Figure S1D).

Combined, these results suggest that the CAGA₁₂-dynGFP reporter is a specific TGF- β /SMAD3 transcriptional reporter, which is as efficient in visualizing the TGF- β /SMAD transcriptional response as the widely used CAGA₁₂-luciferase reporter.

CAGA₁₂-dynGFP reporter shows improved dynamics

Next, we assessed the dynamic characteristics of the CAGA₁₂-dynGFP reporter, and compared its activity with the previously used CAGA₁₂-TdTomato and CAGA₁₂-GFP reporters in B16F10 cells^{18,21,38}. Importantly, CAGA₁₂-dynGFP demonstrated a quicker increase and peak intensity of fluorescent signal upon TGF- β treatment than the TdTomato and GFP reporter (Figure 1C). After 4 hours of TGF- β treatment, 92% of CAGA₁₂-dynGFP cells were fluorescent, which is a significantly faster response when compared to CAGA₁₂-GFP (25%) and CAGA₁₂-TdTomato (29%) ($P < 0.0001$) (Figure 1D). Similarly, the CAGA₁₂-dynGFP reporter showed a significantly faster decrease in fluorescently positive cells upon treatment with TGF- β type I receptor kinase inhibitor SB505124 when compared to CAGA₁₂-GFP and CAGA₁₂-TdTomato ($P < 0.0001$) (Figure 1D). When only 23% of CAGA₁₂-dynGFP reporter cells still showed fluorescent signal after 24 hours of SB505124 treatment, 90% and 86% of cells containing the CAGA₁₂-TdTomato and CAGA₁₂-GFP reporter respectively were still fluorescent (Figure 1D).

Combined, these results show that the CAGA₁₂-dynGFP reporter is superior to both the CAGA₁₂-GFP and CAGA₁₂-TdTomato in reporting TGF- β /SMAD3 signaling in a dynamic manner.



< Figure 1. Generation and validation of the dynamic TGF- β /SMAD3 reporter

(A) Cartoon depicting the TGF- β signaling cascade and activation of the reporter constructs, which are also high-lighted below. MLP: major late promoter, sfGFP: superfolder GFP, dynGFP: dynamic GFP. **(B)** Images of B16F10 cells stably expressing the various TGF- β /SMAD3 reporters treated with TGF- β (1 ng/mL) for 48 h (TdTomato/GFP) or 24 h (dynGFP) or treated with SB505124 (1 μ M) together with TGF- β . **(C)** Flow cytometry of B16F10 cells stably expressing the indicated reporters and treated with TGF- β (1 ng/mL) for 2, 4, 8, 24, and 48 h. SB505124 was added to TGF- β pre-treated (48 h for CAGA12-TdTomato/CAGA12-GFP, 24 h for CAGA12-dynGFP) B16F10 cells. The cut-off for positive cells is shown in the dashed line. **(D)** Relative percentage of positive cells calculated from (C). Area under the curve (AUC) for TGF- β treatment: CAGA12-TdTomato: 4203 \pm 37.01, CAGA12-GFP: 3999 \pm 8.40, CAGA12-dynGFP: 4572 \pm 13.02. AUC for SB505124 treatment: CAGA12-TdTomato: 3974 \pm 34.01, CAGA12-GFP: 3602 \pm 40.66, CAGA12-dynGFP: 2001 \pm 108.9. One-way ANOVA was performed on AUC values, $p < 0.0001$. **(E,F)** The half-life of dynGFP was measured using signal intensity on western blot (E) and relative mean fluorescence intensity (MFI) on flow cytometry (F). Cycloheximide (50 mg/mL) or SB505124 (1 μ M) was added after TGF- β pre-treatment (24 h) of CAGA12-dynGFP B16F10 cells. Statistics for all timepoints were determined using two-way ANOVA, shown for timepoint 4 h. **(G)** The half-life of TdTomato, GFP, and dynGFP were compared by measuring relative MFI on flow cytometry. B16F10 cells were pre-treated with TGF- β (48 h for CAGA12-TdTomato/CAGA12-GFP, 24 h for CAGA12-dynGFP) and treated with cycloheximide (50 mg/mL). Statistics for all timepoints were determined using two-way ANOVA, shown for timepoint 8 h. All experiments were performed in biological triplicates or duplicates (G); error bars represent \pm SEM. *** $P \leq 0.001$, **** $P \leq 0.0001$

The decrease of dynGFP signal in pre-stimulated cells after 24 hours of SB505124 treatment was more pronounced as compared to GFP, although it was slower than initially expected. When cells are treated with SB505124, TGF- β signaling is blocked at the TGF- β type I receptor level. As long as reporter mRNA is present, this still can result in reporter protein synthesis. To assess if this is indeed the case, we determined the half-life of the dynGFP fluorescent reporter protein by inhibiting protein synthesis using cycloheximide (CHX), and compared it to a TGF- β washout, or SB505124 treatment (Figure 1E and 1F). Cells were pre-stimulated with TGF- β for 24 hours so that fluorescence would reach maximal levels, after which the cells were treated with SB505124 or CHX for different time points. Interestingly, we observed that after 4 hours of CHX treatment, fluorescent dynGFP signal was decreased to 48%, compared to 90% with SB505124 treatment, as measured by western blotting (Figure 1E) and flow cytometry (Figure 1F). This indicates that upon blocking TGF- β signaling with SB505124, there is a window in which dynGFP protein synthesis still occurs.

As CHX treatment allows for measuring the half-life of a fluorescent protein, we next compared the breakdown and half-life of the three different reporters. Again, cells were pre-stimulated with TGF- β for 24 (CAGA₁₂-dynGFP) or 48 (CAGA₁₂-TdTomato/GFP) hours so that fluorescence would reach maximal levels, after which they were treated with CHX. For the CAGA₁₂-TdTomato and CAGA₁₂-GFP

reporters, fluorescence signals reduced minimally (~20% drop in fluorescence after 8 hours of CHX, so protein half-lives were estimated to be >24 hours) (Figure 1G). In contrast, dynGFP showed an ~80% drop in fluorescence after 8 hours of CHX, and a half-life of ~4 hours (Figure 1E). Combined, this data again highlights that the CAGA₁₂-dynGFP reporter is superior to both the CAGA₁₂-GFP and CAGA₁₂-TdTomato in reporting TGF- β /SMAD3 signaling in a dynamic manner.


Use of TGF- β reporter for live cell imaging

Our CAGA₁₂-dynGFP reporter has the benefits of lentiviral based vectors and allows for efficient delivery in a broad array of dividing and non-dividing cells. We validated the use of CAGA₁₂-dynGFP reporter as a sensitive and dynamic transcriptional reporter system in various cell lines (attachment and suspension cells, cancer cell lines, non-cancer cell lines and primary cells) (Figure 2A). All cells displayed kinetic activation responses of the reporter, measured on the Incucyte® live cell imaging system, upon treatment with TGF- β for 24 hours (Figure 2B). We calculated the signal over background (s/b) and Z factor (Z' score, Table S3), both important parameters of assay quality when screening compounds for drug discovery. In general, an assay is deemed of sufficient quality for compound testing with an s/b > 2, and a Z' score > 0.5³⁹. Indeed, we exceed those numbers in all but two of the cells lines tested (Table S3). This data suggests the reporter is a great tool for compound screening using live cell imaging.

In Figure S2 we followed the effect of different concentrations of TGF- β on dynGFP signal over the course of 3 days in HepG2, NIH3T3 and B16F10 cells. Higher TGF- β concentrations result in later and longer peaks of dynGFP signal for all cell lines, and a decrease of dynGFP signal at later timepoints. Interestingly, treatment of HepG2 with 10 ng/ml TGF- β results in a second peak, which is easily identified with live cell imaging. These results show that the dynGFP reporter can be used for drug discovery and dynamic monitoring of TGF- β signaling in both attachment and suspension cells, cancer cell lines, non-cancer cell lines and primary cells.

> Figure 2. Application of TGF- β /SMAD dynGFP reporter for live cell imaging in different cell lines

(A) Cells expressing the pLV.CAGA₁₂-dynGFP reporter (Mouse normal mammary gland NMuMG derivative (NM18), human liver cancer cells (HepG2), human acute monocytic leukemia cells (THP1, suspension), mouse endothelial (MS1) and fibroblast cell lines (NIH3T3), and human primary fibroblasts) were stimulated with 2.5 ng/ml TGF- β 3 or 1 ng/ml TGF- β 3 (mouse melanoma cells (YUMM4.1), human and mouse breast cancer cells (MDA-MB-231 and D2.OR). Pictures were taken 24 hours after stimulation on the Incucyte®. **(B)** dynGFP signal was measured for 48 hours upon addition of control (black) or TGF- β (green) on the Incucyte®. dynGFP fluorescence signal was corrected by confluency (%). Higher background fluorescence during early timepoints on the Incucyte® results in slightly elevated signals in control cells.



TGF- β reporter shows heterogenic and dynamic responses to TGF- β

Heterogeneity in intensity, duration or other characteristics of the TGF- β /SMAD3 transcriptional temporal signal could determine cellular response at single cell level³⁶. Therefore, we assessed if cell variation in the temporal behavior of the TGF- β /SMAD3 transcriptional response could be observed at a single cell level using our dynGFP reporter. We combined our dynamic TGF- β transcriptional reporter with a state-of-the-art single cell microscopy technique, where we can automatically segment and track the dynGFP signal in individual cells in real time, in thousands of cells simultaneously. When examining the dynGFP fluorescent intensity within a clonal reporter cell line, we noticed a heterogeneity in signal intensity between cells at a single time point. This is most likely related to slight clonal drift, resulting in differences in gene silencing or expression, and not related to TGF- β response. To assess this, we created a clonal B16F10 SFFV-dynGFP control cell line, which constitutively express the dynGFP fluorophore. Upon measuring dynGFP signal in the B16F10 CAGA₁₂-dynGFP and SFFV-dynGFP clonal lines, we could indeed confirm similar heterogeneity in signal intensity between the lines, concluding that this was the result of technical variation (Figure S3A and B).

We then examined temporal responses in single cells upon TGF- β stimulation. Using clonal B16F10 cell lines containing the CAGA₁₂-dynGFP reporter, the dynGFP signal in individual cells was tracked upon treatment of cells with TGF- β over 24 hours (1440 minutes). We observed variation in the temporal pattern of response over time. When the fluorescent signal was normalized between 0 (blue) and 1 (red) for each cell, presented in a heatmap (Figure 3A), we observed different signaling patterns in TGF- β /SMAD3 transcriptional response. Upon clustering of the different temporal responses of the single cells, different patterns could be observed (Figure S3C), resulting in 3 main clusters within the clonal cell line: early-responders (Figure 3B, E), late responders (Figure 3C and E) and non-responders (Figure 3D). Early responders peaked earlier in their TGF- β reporter response compared to late responders (Figure 3E and F). Similar clustering for early, late and non-responders were observed for the other investigated B16F10 CAGA₁₂-dynGFP clonal line (Figure S4A through G).

Thus, using our CAGA₁₂-dynGFP reporter, we can visualize dynamics in TGF- β induced transcription in single cells over time. Using this approach, we can cluster different signaling responses which could have consequences for biological outcome of the signaling.




Figure 3. The TGF- β /SMAD3 dynGFP reporter can be used to identify heterogenous TGF- β /SMAD3 responses on single cell level

(A) Heatmap showing the increase of relative dynGFP intensity between 0 (blue) and 1 (red) of live cell imaging for 24 hours of individual B16F10 melanoma cells stably expressing CAGA12-dynGFP (Clone 7 population). Cells were stimulated with TGF- β 1 (1 ng/ml) during the 24 hours of imaging (B, C, D) The dynamic TGF- β /SMAD3 dynGFP response in B16F10 cells can be divided in three distinct clusters; early responders (B), late-responders (C) and non-responders (D). (E) Early TGF- β /SMAD3 dynGFP responders show an increase and plateau in dynGFP signal earlier after TGF- β stimulation compared to late-responders. (F) Histogram plot reveals that the timing of the peak in dynGFP signal after TGF- β stimulation differs between early- and late-responders.

Application of TGF- β reporter in 3D cell culture systems

Organoids are 3-dimensional (3D) *in vitro* cell cultures that resemble some of the key features of an organ. They are important tools that more closely mimic *in vivo* biology than 2D or 3D spheroid-type co-cultures, and especially colorectal cancer organoids are widely used⁴⁰. About 40% of colorectal cancer

(CRC) patients harbor mutations in the TGF- β signaling pathway, often rendering SMAD3/4 canonical transcription unresponsive^{41,42}. However, 60% of CRC patients have an intact TGF- β /SMAD3 canonical pathway. We stably introduced the CAGA₁₂-dynGFP reporter in colorectal cancer organoids that did not harbor mutations in TGF- β signaling pathway components by lentiviral transduction and assessed the SMAD3-driven transcriptional response after TGF- β stimulation. No or limited endogenous TGF- β signaling occurred in these organoids as no fluorescence was observed at baseline (Figure 4A, B), but upon addition of exogenous TGF- β , CAGA₁₂-dynGFP accumulation was observed in the entire organoid (Figure 4A, B). A decrease of the signal could be observed over time. This indicates that the dynGFP reporter can be used to assess TGF β transcriptional signaling kinetics in a colorectal cancer organoid model.

Visualizing endogenous TGF- β signaling *in vitro* and *in vivo*

The tumor microenvironment, including fibroblasts, plays an important role in supporting tumor growth⁴³. Latent TGF- β in the tumor microenvironment can be locally activated by the interplay between cancer cells and fibroblasts, creating a local niche containing active TGF- β signaling^{4,43}. Using the CAGA₁₂-dynGFP fluorescent reporter, we aimed to visualize endogenous TGF- β signaling within fibroblast-containing tumor microenvironments.

First, we assessed if the CAGA₁₂-dynGFP reporter is able to report endogenous TGF- β activity in a pancreatic cancer organoid model co-cultured with pancreatic stellate cells (RLT-PSCs). Pancreatic cancer organoids that are wildtype in TGF- β pathway components were used, and RLT-PSCs expressing H2B-mRuby were transduced with the dynGFP reporter and selected using FACS sort. On day 0 of the experiment, organoid co-cultures were treated with TGF- β 3, A83-01 (TGF- β receptor I inhibitor), or endogenous conditions. After stimulation of the co-culture with TGF- β for 3 and 5 days, activation of the dynGFP reporter was seen in some, but not all fibroblasts (Figure 4C). Upon TGF- β stimulation, dynGFP signal could be seen in RLT-PSCs on the rim as well as within the organoid core (Figure 4C). With the addition of A83-01, no dynGFP signal was observed. Interestingly, under endogenous conditions, dynGFP signal could be observed in RLT-PSCs in the core of the organoids (Figure 4C). When blocking TGF- β signaling with A83-01 after 4 days of endogenous conditions, the endogenous dynGFP signal could be reduced (Figure 4C), indicating that the dynGFP signal is indeed TGF- β dependent. This suggests that the dynGFP reporter is capable of picking up endogenous levels of TGF- β .




Figure 4. Application of CAGA₁₂-dynGFP reporter in 3D and *in vivo*

(A) Colorectal cancer organoids P26T were stimulated with TGF- β (1 ng/ml) for 7 hours. Stimulated organoids show an increase in dynGFP signal. **(B)** Quantified dynGFP signal of A) of control (n= 4) and TGF- β treated (n= 10) organoids. **(C)** Immortalized fibroblasts RLT-PSCs expressing H2B-mRuby and CAGA₁₂-dynGFP were selected for CAGA₁₂-dynGFP transduction through puromycin selection and FACS sorting. Co-cultures of RLT-PSC fibroblasts with PDAC organoids were stimulated with TGF- β 1 (5 ng/ml), A83-01 (500 nM) or endogenous conditions up to 5 days. Upon exogenous TGF- β stimulation, dynGFP expression in some RLT-PSCs was observed. Upon 3 days of culturing in endogenous conditions, dynGFP expression could be found in RLT-PSCs located in organoid core. Endogenous CAGA₁₂-dynGFP could be blocked by addition of A83-01 at day 4. Pictures are representative of n=5. **(D)** PYMT organoids originating from MMTV-PyMT;R26-mTmG transgenic FVB mice were transduced with CAGA₁₂-dynGFP reporter and selected through FACS sorting. Upon transplantation of these organoids in the mammary fat pad of FVB mice, intravital imaging was performed through surgical exposure. Cell membranes were tagged with TdTomato through an N-terminal membrane tag (mTdTomato, shown in magenta), second harmonic generation (SHG) signal, showing collagen-1 fibers for structural information, is shown in grey. Green cytoplasmic dynGFP signal can be visualized.

To test whether the CAGA₁₂-dynGFP reporter can be used to visualize endogenous TGF- β signaling *in vivo* as well, the reporter was transduced into PYMT organoids derived from MMTV-*PyMT* and *R26-mTmG* mice, which were subsequently FACS sorted for dynGFP expression (Figure S5A)^{32,33}. *In vitro*, endogenous TGF- β signaling was observed in only few cells within the PyMT organoids (Figure S5B). After TGF- β treatment, an increase of dynGFP expression was observed, resulting in a heterogenous intensity pattern of dynGFP. Upon transplantation of these organoids into the mammary fat pad of FVB mice to create primary mammary tumors, intravital imaging was performed through surgical exposure of the tumors. Membranous TdTomato (mTdTomato) is shown in Magenta, Second Harmonic Generation (SHG, in grey) represents the type-I collagen network to provide structural information. *In vivo*, endogenous CAGA₁₂-dynGFP signal was observed in the PyMT primary tumors (Figure 4D). A heterogenous pattern in dynGFP signal was observed throughout the tumors, similar to the heterogeneity observed upon stimulation with TGF- β *in vitro* (Figure 4D, zoom, Figure S5B). In summary, the lentiviral CAGA₁₂-dynGFP construct can be widely applied in different 2D and 3D culture systems, as well as in biologically relevant contexts *in vivo*.

Discussion

TGF- β is a highly context dependent cytokine that elicits its multifunctional effects via intracellular SMAD transcriptional effectors, of which the activity is determined by the integration of diverse extracellular and internal cues. Visualization of the dynamic aspects of TGF- β /SMAD-induced transcriptional responses will allow for refining and provide novel insights into the role of temporal behavior of SMAD signaling in physio-pathological processes and consequences of pharmacological/(epi)genetic manipulation. However, folding and degradation time of fluorescent proteins limits the ability of fluorescent transcriptional reporters to reflect dynamics in signaling. By using a quickly folded and highly unstable fluorescent GFP, we were able to create a TGF- β /SMAD3 reporter that allows monitoring of SMAD3-driven transcriptional temporal responses in single living cells. Using this reporter in a clonal B16F10 melanoma cell line, we observed heterogeneity in TGF- β /SMAD3-induced transcriptional response, distinguishing slow, fast and non-responders. We further highlight the use of this reporter in different 2D cell culture and 3D organoid (co-) culture, as well as in a biologically relevant context *in vivo* using intravital imaging. These observations will promote studies in which the

activity/expression or localization of signaling molecules requires (single cell) time-lapse imaging of thousands of living cells, and studies on (endogenous) TGF- β signaling dynamics *in vitro* and *in vivo*.

To study TGF- β /SMAD-induced transcription, luciferase-based reporters coupled with multimerized SMAD3/4 binding elements have been used extensively in literature, both *in vitro* and *in vivo*^{11,12,15,44-47}. Zhu and colleagues used the CAGA₁₂-luciferase reporter in breast cancer cells to study TGF- β /SMAD3 activity by measuring luminescence during tumorigenesis *in vivo*, while others created a transgenic CAGA₁₂-luciferase mouse, studying TGF- β /SMAD3 response to injury^{45,48}. To achieve a more dynamic visualization with the CAGA₁₂-luciferase reporter, Sorre and colleagues coupled a nano luciferase (NLuc) as reporter to the CAGA₁₂ box and used microfluidic technology to apply a unstable NLuc substrate prior to image signal readout¹¹. This setup, however, requires specialized microfluidics equipment and operator expertise, and is therefore not easily adaptable by other laboratories. Moreover, luciferase-based assays *in vivo* do not allow for a single-cell resolution.

Fluorescent transcriptional reporters allow for single-cell resolution. However, since the protein half-life of fluorophores can be long (e.g. > 24 hours for GFP), signaling dynamics cannot be appropriately studied with the current reporters. The half-life of our new dynGFP reporter is significantly reduced (~4 hours) and is therefore, in combination with enhanced protein folding, better suited to study signaling dynamics. The sensitivity of our reporter will however be dependent on the sensitivity of the experimental-readout, the sensitivity of the cell line and the level of integration of the lentiviral reporter. The current improvements were made on protein level. Additionally, to enhance instability of the dynGFP reporter on mRNA level, a destabilable polyA tail could be added⁴⁹. However, this is not suited for lentiviral vectors as an additional polyA tail behind the gene of interest in lentiviral vectors reduces viral titers.

The CAGA₁₂-dynGFP reporter can be used in live cell imaging systems like the Incucyte[®] to assess the dynamic response to TGF- β in a bulk population of cells. This is a very suitable set-up for examining e.g. the effect of drug responses on TGF- β activity. However, this system is less qualified to observe different responses to TGF- β between single cells, due to its limited resolution and capability to track single cells over time. Using microscope systems specialized for single cell imaging, CAGA₁₂-dynGFP increases can be monitored in single cells to study TGF- β responses over time.

Some limitations of the reporter should also be discussed. We used clonal B16F10 CAGA₁₂-dynGFP cells to investigate TGF- β responses throughout the cell cycle. We observed a higher CAGA₁₂-dynGFP signal in later phases of the cell cycle, however, using a clonal control cell line constitutively expressing dynGFP, we observed a very similar pattern. We therefore encourage the use of a constitutive control reporter in addition to the dynGFP for cell-cycle related studies.

The dynamic TGF- β /SMAD3 reporter is highly suited for investigating dynamic responses to TGF- β in different settings. However, as heterogeneity in dynGFP intensity within a (clonal) CAGA₁₂-dynGFP cell line can exist for technical reasons, we encourage the use of the reporter for studying TGF- β responses over time, in contrast to comparing reporter signal at a single time point. At last, we noted a difference in fluorescence reporter activity 48 hours after a single TGF- β treatment (when comparing Figure 1C and Figure S2A). We hypothesize that these differences are the result of difference in confluency and well size, which resulted in a different TGF- β turnover. Cause and proper controls should be taken when interpreting these results.

Visualizing endogenous dynamic TGF- β /SMAD3 induced responses without addition of exogenous TGF- β in biologically relevant environments *in vitro* or *in vivo* may provide novel insights. Based on our *in vitro* results, the reporter can pick up (exogenously stimulated) TGF- β levels as low as 0.04 ng/ml in various cell lines. This is sensitive enough to pick up endogenous TGF- β levels in tissues, as we observed dynGFP⁺ cells in organoid co-cultures of fibroblasts and pancreatic cancer cells, and *in vivo* in mouse mammary tumors. This reporter can visualize both paracrine and autocrine signaling, and it will be interesting to distinguish between the two using additional controls. In mouse mammary tumors, we could observe a heterogeneous pattern of TGF- β signaling within the tumor. These heterogeneous patterns were also observed *in vitro* upon TGF- β stimulation, showing that the *in vivo* (endogenous) TGF- β activation mimics TGF- β stimulation *in vitro*. As the cells were not sorted to a single cell clone, this heterogeneity could be due to cellular difference in incorporation of the reporter (Figure 3). Alternatively, the heterogeneity in intensity is the result of heterogeneity in response, similar to what Zhu and colleagues observed when treating breast cancer cells to TGF- β . These researchers used the CAGA₁₂-TdTomato reporter in the MDA-MB-231 breast cancer cells, and observe a population showing no TdTomato signal upon TGF- β treatment, as well as populations showing low, medium and high TdTomato signal. It would be interesting to use the dynamic CAGA₁₂-dynGFP reporter in this case to follow

these dynamics over time²¹. Also, Giampieri *et al* used a CAGA₁₂-CFP reporter and SMAD2 nuclear translocation to monitor TGF- β signaling in primary breast cancer and lymph node metastasis¹⁸. They also reported a heterogeneity in CAGA₁₂-CFP signal in primary MTLn3E tumors, similar to the heterogeneity we observed in PYMT tumors. Additionally, Giampieri reported that, upon metastasizing to the lymph node, breast cancer cells lost their motility. Motile cells in the primary tumor were mostly CAGA₁₂-CFP positive. Interestingly, once metastasized to the lymph nodes, they observed mostly non-motile, CAGA₁₂-CFP negative cells in late lymph node metastasis, suggesting that the TGF- β /SMAD3 transcriptional response during lymph node metastasis is transient¹⁸. Taken the results together it would be of interest to examine the contribution of TGF- β /SMAD3 signaling dynamics during lymph node metastasis of breast cancer cells containing the CAGA₁₂-dynGFP reporter by performing long-term intravital imaging.

In conclusion, the new TGF- β reporter presented in this study shows to be beneficial over existing TGF- β transcriptional reporters, because of the enhanced folding and degradation of the dynGFP protein. This allows for new (drug) discoveries in TGF- β signaling dynamics. The lentiviral backbone and the simplicity of the system make it easily adaptable to different cell systems, including single cell imaging, 3D organoid culture, and intravital imaging. The easy and quantitative read-out of CAGA₁₂-dynGFP signal in stably transfected cells using live-imaging high-content experiments can be readily performed. Its robust signal allows for high quality assays to be used in drug discovery. Because of the many roles of TGF- β in different processes and cell types, this reporter can be of value in many fields of biological research.

Acknowledgments

We would like to acknowledge all (former) members of the Ritsma and ten Dijke lab for help, support and critical comments, Willem Sloos, Lennert Janssen and Cecile Beerens for their technical support and the LUMC FACS sort facility for their flow cytometry support. We thank Gonzalo Sanchez Duffhues and Marie-José Goumans for their valuable comments on the manuscript.

References

1. Sonnen, K. F. & Aulehla, A. Dynamic signal encoding-From cells to organisms. *Seminars in Cell and Developmental Biology* vol. 34 91–98 Preprint at <https://doi.org/10.1016/j.semcdb.2014.06.019> (2014).
2. Purvis, J. E. & Lahav, G. Encoding and decoding cellular information through signaling dynamics. *Cell* vol. 152 945–956 Preprint at <https://doi.org/10.1016/j.cell.2013.02.005> (2013).
3. Zi, Z., Chapnick, D. A. & Liu, X. Dynamics of TGF- β /Smad signaling. *FEBS Letters* **586**, 1921–1928 (2012).
4. Massagué, J. TGF β signalling in context. *Nature Reviews Molecular Cell Biology* vol. 13 616–630 Preprint at <https://doi.org/10.1038/nrm3434> (2012).
5. Miller, D. S. J., Schmierer, B. & Hill, C. S. TGF- β family ligands exhibit distinct signalling dynamics that are driven by receptor localisation. *Journal of cell science* **132**, (2019).
6. Nicklas, D. & Saiz, L. Computational modelling of smadmediated negative feedback and crosstalk in the TGF- β superfamily network. *Journal of the Royal Society Interface* **10**, (2013).
7. Kang, Y., Chen, C. R. & Massagué, J. A self-enabling TGF β response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. *Molecular Cell* **11**, 915–926 (2003).
8. Jullien, J. & Gurdon, J. Morphogen gradient interpretation by a regulated trafficking step during ligand-receptor transduction. *Genes and Development* **19**, 2682–2694 (2005).
9. Strasen, J. *et al.* Cell-specific responses to the cytokine TGF β are determined by variability in protein levels. *Molecular Systems Biology* **14**, (2018).
10. Zi, Z. *et al.* Quantitative analysis of transient and sustained transforming growth factor- β signaling dynamics. *Mol Syst Biol* **7**, 492 (2011).
11. Sorre, B., Warmflash, A., Brivanlou, A. H. & Siggia, E. D. Encoding of temporal signals by the TGF- β Pathway and implications for embryonic patterning. *Developmental Cell* **30**, 334–342 (2014).
12. Dennler, S. *et al.* Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J* **17**, 3091–100 (1998).
13. Kang, Y. Imaging TGF β Signaling in Mouse Models of Cancer Metastasis. *Methods in molecular biology (Clifton, N.J.)* **1344**, 219–232 (2016).
14. Korpál, M. *et al.* Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. *Nature medicine* **15**, 960–966 (2009).
15. Warmflash, A. *et al.* Dynamics of TGF- β signaling reveal adaptive and pulsatile behaviors reflected in the nuclear localization of transcription factor Smad4. *Proc Natl Acad Sci U S A* **109**, E1947–E1956 (2012).
16. Frick, C. L., Yarka, C., Nunns, H. & Goentoro, L. Sensing relative signal in the Tgf- β /Smad pathway. *Proceedings of the National Academy of Sciences of the United States of America* **114**, E2975–E2982 (2017).
17. Tidin, O., Friman, E. T., Naef, F. & Suter, D. M. Quantitative relationships between SMAD dynamics and target gene activation kinetics in single live cells. *Sci Rep* **9**, 1–11 (2019).
18. Giampieri, S. *et al.* Localized and reversible TGF β signalling switches breast cancer cells from cohesive to single cell motility. *Nat Cell Biol* **11**, 1287–1296 (2009).
19. Vizán, P. *et al.* Controlling long-term signaling: Receptor dynamics determine attenuation and refractory behavior of the TGF- β pathway. *Science Signaling* **6**, ra106–ra106 (2013).
20. Vizán, P., Miller, D. S. J., Schmierer, B. & Hill, C. S. Response to comment on 'controlling long-term signaling: Receptor dynamics determine attenuation and refractory behavior of the TGF- β pathway'-Smad2/3 activity does not predict the dynamics of transcription. *Science Signaling* **7**, 1c2 (2014).
21. Luwor, R. B. *et al.* Single live cell TGF- β signalling imaging: breast cancer cell motility and migration is driven by sub-populations of cells with dynamic TGF- β -Smad3 activity. *Molecular Cancer* **14**, 50 (2015).
22. Dennler, S. *et al.* Direct binding of Smad3 and Smad4 to critical TGF β -inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO Journal* **17**, 3091–3100 (1998).
23. Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: Competitive inhibitors of small RNAs in mammalian cells. *Nature Methods* **4**, 721–726 (2007).
24. Pédelacq, J. D., Cabantous, S., Tran, T., Terwilliger, T. C. & Waldo, G. S. Engineering and characterization of a superfolder green fluorescent protein. *Nature Biotechnology* **24**, 79–88 (2006).
25. Rak, J. W., McEachern, D. & Miller, F. R. Sequential alteration of peanut agglutinin binding-glycoprotein expression during progression of murine mammary neoplasia. *British Journal of Cancer* **65**, 641–648 (1992).
26. Deckers, M. *et al.* The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells. *Cancer research* **66**, 2202–2209 (2006).
27. Jesnowski, R. *et al.* immortalization of pancreatic stellate cells as an *in vitro* model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteine. *Laboratory investigation; a journal of technical methods and pathology* **85**, 1276–1291 (2005).
28. Zhang, L. *et al.* USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF- β type I receptor. *Nature Cell Biology* **14**, 717–726 (2012).
29. van de Wetering, M. *et al.* Prospective derivation of a living organoid biobank of colorectal cancer patients. *Cell* **161**, 933–945 (2015).
30. Boj, S. *et al.* Organoid models of human and mouse ductal pancreatic cancer. *Cell* **160**, 324–338 (2015).
31. Persson, U. *et al.* The L45 loop in type I receptors for TGF- β family members is a critical determinant in specifying Smad isoform activation. *FEBS Lett* **434**, 83–87 (1998).

32. Lin, E. *et al.* Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. *The American journal of pathology* **163**, 2113–2126 (2003).
33. Muzumdar, M. M. D. *et al.* A global double-fluorescent Cre reporter mouse. *Genesis (New York, N.Y. : 2000)* **45**, 593–605 (2007).
34. Snippert, H. J. *et al.* Intestinal Crypt Homeostasis Results from Neutral Competition between Symmetrically Dividing Lgr5 Stem Cells. *Cell* **143**, 134–144 (2010).
35. Bornes, L. *et al.* Fsp1-Mediated Lineage Tracing Fails to Detect the Majority of Disseminating Cells Undergoing EMT. *Cell Rep* **29**, (2019).
36. You, L. *et al.* Linking the genotypes and phenotypes of cancer cells in heterogenous populations via real-time optical tagging and image analysis. *Nature biomedical engineering* (2022) doi:10.1038/S41551-022-00853-X.
37. Andreatta, C. *et al.* Use of short-lived green fluorescent protein for the detection of proteasome inhibition. *BioTechniques* vol. 30 656–660 Preprint at <https://doi.org/10.2144/01303dd03> (2001).
38. Stuelten, C., Kamaraju, A., Wakefield, L. & Roberts, A. Lentiviral reporter constructs for fluorescence tracking of the temporospatial pattern of Smad3 signaling. *BioTechniques* **43**, 289–294 (2007).
39. Hughes, J. P., Rees, S. S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. *British Journal of Pharmacology* **162**, 1239 (2011).
40. Tuveson, D. & Clevers, H. Cancer modeling meets human organoid technology. *Science* **364**, 952–955 (2019).
41. Markowitz, S. *et al.* Inactivation of the type II TGF- β receptor in colon cancer cells with microsatellite instability. *Science (New York, N.Y.)* **268**, 1336–1338 (1995).
42. Markowitz, S. & Bertagnolli, M. Molecular origins of cancer: Molecular basis of colorectal cancer. *The New England journal of medicine* **361**, 2449–2460 (2009).
43. Sahai, E. *et al.* A framework for advancing our understanding of cancer-associated fibroblasts. *Nature reviews. Cancer* **20**, 174–186 (2020).
44. Oshimori, N., Oristian, D. & Fuchs, E. TGF- β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma. *Cell* **160**, 963–976 (2015).
45. Chen, H., Ware, T. M. B., Iaria, J. & Zhu, H. J. Live cell imaging of the TGF- β /Smad3 signaling pathway *in vitro* and *in vivo* using an adenovirus reporter system. *Journal of Visualized Experiments* **2018**, (2018).
46. L, Z. *et al.* Human Smad3 and Smad4 are sequence-specific transcription activators. *Molecular cell* **1**, 611–617 (1998).
47. LJ, J., S, I., CH, H., P, ten D. & W, K. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor- β , activin, and bone morphogenetic protein-inducible enhancer. *The Journal of biological chemistry* **273**, 21145–21152 (1998).
48. Lin, A. H. *et al.* Global Analysis of Smad2/3-Dependent TGF- β Signaling in Living Mice Reveals Prominent Tissue-Specific Responses to Injury. *The Journal of Immunology* **175**, 547–554 (2005).
49. Zubiaga, A. M., Belasco, J. G. & Greenberg, M. E. The nonamer UUAUUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. *Molecular and Cellular Biology* **15**, 2219–2230 (1995).




Figure S1. Validation of the CAGA₁₂-dynGFP reporter

(A) CAGA₁₂-luc and CAGA₁₂-dynGFP assays show that B16F10 cells are highly responsive to TGF-β (1 ng/ml) ($p < 0.0001$), which can be blocked by SB505124 ($p < 0.0001$). No background TGF-β signalling is seen (n.s. compared to SB505124 (1 μM) treatment). CAGA₁₂-luc was measured on plate reader and corrected for β-gal expression. CAGA₁₂-dynGFP signal was measured on plate reader and corrected for confluence, measured on Incucyte®S3, showing comparable results to CAGA₁₂-luc reporter. (B,C) TGF-β 1,2 and 3 stimulation result in increased levels of phosphorylated SMAD2 (pSMAD2) and dynGFP signal, while stimulation with BMP ligands show phosphorylation of SMAD1 (B, western blot), but do not result in an increase in CAGA₁₂-dynGFP signal (C, flow cytometry) (D) Increase and decrease of p-SMAD2, dynGFP and PAI-1 upon TGF-β3 and SB505124 (cells pretreated with TGF-β3 (1 ng/ml) for 24 hours). (E) TGF-β1 and TGF-β3 result in similar CAGA₁₂-dynGFP activation in B16F10 CAGA₁₂-dynGFP cells. Increase in dynGFP fluorescence signal corrected by confluence is shown over time after addition of different concentrations of TGF-β1 (left) and TGF-β3 (right).




Figure S2.

DynGFP signal dynamics of the CAGA₁₂-dynGFP reporter activity in response to TGF-β3 in HepG2, NIH3T3 and B16F10 cell lines. Cells are stimulated with the indicated concentrations of TGF-β over time. dynGFP fluorescence signal was corrected by confluence (%).




Figure S3. dynGFP signal intensity and responses in CAGA12-dynGFP reporter and control clonal cell line

(A) B16F10 CAGA₁₂-dynGFP clone 7 cells show a heterogeneous distribution of dynGFP signal upon stimulation with TGF- β 1, shown in normalized cell count. **(B)** Control clonal cell line B16F10 SFFV-dynGFP shows a heterogeneous distribution of dynGFP signal, shown in absolute cell count. **(C)** The dataset derived from Figure 3A could be classified into different groups via Euclidean distance-based hierarchical clustering analysis.




Figure S4. Heterogeneous TGF- β /SMAD responses at the single cell level

(A) Heatmap of dynGFP responses of B16F10 CAGA₁₂-dynGFP clone 9 after stimulation with TGF- β 1 (1 ng/ml) for 24 hours. Relative signal between 0 (blue) and 1 (red) of 1200 cells. **(B)** Histogram showing heterogeneity in levels of dynGFP signal (TGF- β level) in B16F10 CAGA₁₂-dynGFP clone 9 at 24 hours. **(C, D, E)** Upon clustering of the dynGFP signal after TGF- β 1 stimulation, early-responder (C), late-responder (D) and non-responder (E) clusters were identified. **(F, G)** Early responders show a peak and plateau earlier after TGF- β stimulation compared to late-responders.




Figure S5. CAGA-dynGFP reporter activity of PyMT organoids *in vitro*

(A) PyMT organoids from MMTV-PyMT;R26-mTmG transgenic FVB mice were transduced with CAGA₁₂-dynGFP and were FACS sorted for dynGFP expression after treatment with TGF- β 1 for 48 hours. **(B)** In control medium, dynGFP signal can be observed in few cells in CAGA₁₂-dynGFP PyMT organoids *in vitro* (indicated by white arrows, representative of 10 organoids). Upon TGF- β 1 stimulation for 48 hours, the dynGFP signal is increased.

Table S1. Cloning and sequencing primers

Cloning primers	5'→3'
T7 FW	taatacgactcactataggg
CAGA ₁₂ +MLP FW	tttatcgataggtaccgagctc
CAGA+MLP + age1 REV	cgtataccggtggatcag
D2 domain FW	ggacgagctgtacaagaag
D2 domain REV	ctgcagaattc ttacacattgatcctagcagaagc
eGFP FW	catggctctgctggagttcgtg
eGFP REV	cgtcgccgtccagctcgaccag
PGK REV	cggtggatgtggaatgtgtg

Table S2. rt-qPCR primers

Gene	Forward (5'→3')	Reverse (5'→3')
<i>GFP</i>	AAGCTGACCCTGAAGTTCATCTGC	TCCAGCAGGACCATGTGATC
<i>dynGFP</i>	GTCGAGCTGGACGGCGACGTA	CACGAAGTCCAGCAGGACCATG
<i>Smad7</i>	TGGATGGCGTGTGGGTTTA	TGGCGGACTTGATGAAGATG
<i>Serpine1</i>	GCCAACAAGAGCCAATCACA	AGGCAAGCAAGGGCTGAAG
<i>Ctgf</i>	GGCCTCTTCTGCGATTTTCG	CCATCTTTGGCAGTGCACACT
<i>Gapdh</i>	CCAAGTCGGATGTGGAAATGG	TGTCGCAAGTGGACAGTCTC
<i>Hprt</i>	TGGATACAGGCCAGACTTTGTT	CAGATTCAACTGCGCTCATC

Table S3. Calculated s/b and Z0 scores per cell line

Cell line	max intensity (timepoint)	Z' score	s/b score
D2.OR	28 hours	0.535	309.523
YUMM4.1	24 hours	0.810	131.223
NIH3T3	21 hours	0.918	205.973
Fibroblasts	30 hours	-1.175	3.680
NM18	21 hours	0.878	384.960
MDA	30 hours	0.880	474.589
THP1	21 hours	0.835	2043.514
HepG2	33 hours	0.425	17.605
MS1	30 hours	0.524	43.081